Sequelae of Lassa Fever
Sequelae of Lassa Fever
批准号:
10326863
负责人:
Slobodan Paessler
金额:
$72.73万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
未结题
起止时间:
2018-02-09 至 2025-01-31
关键词:
Acoustic NerveAcuteAddressAdoptive TransferAffectAfricaAnimal ModelAnimalsAnnual ReportsAuditoryBehaviorCD3 AntigensCase StudyClinicalContainmentConvalescenceDataDevelopmentDiseaseEtiologyExhibitsFutureGoalsHealth systemHemorrhageHomeHospitalsHumanImmuneImmunologicsImmunologyIndividualInfectionInjuryInterferon-alphaLabyrinthLassa FeverLassa virusLiteratureLocationMeasuresMediatingMedicalModelingMolecular VirologyMusNeuraxisNeurologicNeuronsNeurosciencesNewborn InfantNigeriaPathogenesisPathologicPatientsPhasePhysiologicalPlant RootsPrevalenceProcessPublic HealthQuality of lifeResearchRodent ModelRoleRoutine Diagnostic TestsSensorySudden Hearing LossSurvivorsSymptomsSystemic infectionT cell responseT-Cell DepletionT-LymphocyteTNFSF6 geneTechniquesTimeTissuesUnited StatesViral AntigensVirus Diseasesauditory pathwaybaseclinical diagnosticsexperimental studyfunctional disabilitygain of functionhearing impairmenthearing screeningmortalitymouse modelnoninvasive diagnosisnovelperforinpreventrecruittool
中文摘要
项目总结
英文摘要
PROJECT SUMMARY
Hearing loss is one of the most prevalent sensory deficits that affect one in five individuals in the United States.
While the underlying etiology can vary widely, viral infections are speculated to be associated with hearing loss
with a sudden onset. Lassa fever (LF), caused by Lassa virus (LASV), is a major public health threat in West
Africa and is characterized by acute hemorrhagic disease and/or neurological sequelae, and up to 500,000
cases are reported annually. Approximately 30% of LF survivors develop sudden onset hearing loss weeks or
months after leaving the hospital, placing a huge burden on the public health system and impacting patients'
quality of life. This phenomenon is quite unique because it typically develops at later stages of the disease
process, thus making LF the only viral infection described in medical literature that induces hearing loss mostly
in the convalescence phase. Until now, the lack of a robust animal model exhibiting sudden onset hearing loss
induced by LASV prevented the mechanistic study of this clinical feature. To address this need, we developed
a novel murine model for LF that mimics many symptoms of human LF. Most importantly, our model
consistently reproduced the hearing loss in animals that were recovering from infection. This powerful tool will
allow us, for the first time, to study the pathogenesis of hearing loss associated with LF, in a maximum
containment BSL-4 setting.
The long-term goal of our research is to identify the immunological and pathological mechanisms responsible
for LASV-induced hearing loss in human patients to enable future treatment. The objective of this application is
to use our physiologically relevant LF mouse model to study the mechanism of LF associated hearing loss, as
well as to assess auditory damage of LF survivors in West Africa. Therefore, we propose the following
Specific Aims: 1. Determine the mechanism of hearing loss in LASV-infected Stat1-/- mice. We will investigate
the underlying mechanism by focusing on the inner ear, as well as determining the involvement of the central
nervous system in hearing loss, by studying the auditory behavior of infected mice in order to define the
localization of the injury and assess histopathological changes in the inner ear. 2. Identify the role of T cells in
the development of hearing loss by performing loss/gain of function experiments. We will utilize T cell depletion
and adoptive transfer techniques to determine the contribution of T cells to hearing loss in infected Stat1-/-
mice. We will also identify the viral antigen most essential for T cell recruitment to the auditory nerve. 3.
Determine the degree of hearing loss and location of functional damage in human patients exhibiting SHL after
surviving LASV infection. We propose to investigate the underlying the hearing loss in documented LF
survivors in Nigeria by using noninvasive diagnostic tests routinely performed during newborn hearing
screening in the USA.
期刊论文(20)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
COVID-19 Subclinical Infection and Immunity: A Review.
COVID-19-Subclinical感染和免疫力:综述。
DOI:
10.4103/njm.njm_85_21
发表时间:
2021-11
期刊:
Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria
影响因子:
--
作者:
[Bartekwa JW, Abene EE, Luka PD, Yilgwan CS, Shehu NY]
通讯作者:
Shehu NY
DOI:
10.1371/journal.pntd.0006187
发表时间:
2018-03
期刊:
PLoS neglected tropical diseases
影响因子:
3.8
作者:
[Mateer EJ, Huang C, Shehu NY, Paessler S]
通讯作者:
Paessler S
DOI:
10.3389/fcimb.2018.00251
发表时间:
2018
期刊:
Frontiers in cellular and infection microbiology
影响因子:
5.7
作者:
[Mateer EJ, Paessler S, Huang C]
通讯作者:
Huang C
Confocal Imaging of Double-Stranded RNA and Pattern Recognition Receptors in Negative-Sense RNA Virus Infection.
负义 RNA 病毒感染中双链 RNA 和模式识别受体的共聚焦成像。
DOI:
10.3791/59095
发表时间:
2019
期刊:
Journal of visualized experiments : JoVE
影响因子:
--
作者:
[Mateer,Elizabeth, Paessler,Slobodan, Huang,Cheng]
通讯作者:
Huang,Cheng
DOI:
10.14202/ijoh.2023.10-14
发表时间:
2023-01
期刊:
International journal of one health
影响因子:
--
作者:
[]
通讯作者:
共 11 条
Recombinant life attenuated vaccine against Argentine hemorrhagic fever
-
批准号:8637909
-
项目类别:
-
资助金额:$96.41万
-
财政年份:2011
-
负责人:Slobodan Paessler
-
依托单位:
Recombinant life attenuated vaccine against Argentine hemorrhagic fever
-
批准号:8076684
-
项目类别:
-
资助金额:$90.18万
-
财政年份:2011
-
负责人:Slobodan Paessler
-
依托单位:
Recombinant life attenuated vaccine against Argentine hemorrhagic fever
-
批准号:8449743
-
项目类别:
-
资助金额:$90.42万
-
财政年份:2011
-
负责人:Slobodan Paessler
-
依托单位:
Recombinant life attenuated vaccine against Argentine hemorrhagic fever
-
批准号:8250336
-
项目类别:
-
资助金额:$86.53万
-
财政年份:2011
-
负责人:Slobodan Paessler
-
依托单位:
Advance Veterinary Services
-
批准号:7262331
-
项目类别:
-
资助金额:$17.24万
-
财政年份:2006
-
负责人:Slobodan Paessler
-
依托单位:
VEE PATHOGENESIS AND VACCINE DEVELOPMENT
-
批准号:6875255
-
项目类别:
-
资助金额:$11.26万
-
财政年份:2004
-
负责人:Slobodan Paessler
-
依托单位:
VEE PATHOGENESIS AND VACCINE DEVELOPMENT
-
批准号:7038300
-
项目类别:
-
资助金额:$11.53万
-
财政年份:2004
-
负责人:Slobodan Paessler
-
依托单位:
VEE PATHOGENESIS AND VACCINE DEVELOPMENT
-
批准号:7208981
-
项目类别:
-
资助金额:$11.82万
-
财政年份:2004
-
负责人:Slobodan Paessler
-
依托单位:
VEE PATHOGENESIS AND VACCINE DEVELOPMENT
-
批准号:6769005
-
项目类别:
-
资助金额:$9.92万
-
财政年份:2004
-
负责人:Slobodan Paessler
-
依托单位:
Advance Veterinary Services
-
批准号:7473997
-
项目类别:
-
资助金额:$93.8万
-
财政年份:--
-
负责人:Slobodan Paessler
-
依托单位:
Advance Veterinary Services
-
批准号:8080174
-
项目类别:
-
资助金额:$214.29万
-
财政年份:--
-
负责人:Slobodan Paessler
-
依托单位:
Advance Veterinary Services
-
批准号:7665118
-
项目类别:
-
资助金额:$171.43万
-
财政年份:--
-
负责人:Slobodan Paessler
-
依托单位:
海外基金